Belatacept Resistant Rejection is Associated with CD28(+) Memory CD8 T cells

Recently newer therapies have been designed to more specifically target rejection in an effort to improve efficacy and limit unwanted toxicity. Belatacept, a CD28-CD80/86 specific reagent is associated with superior patient survival and graft function than traditional therapy but its adoption as a m...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Am J Transplant
Asıl Yazarlar: Mathews, DV, Wakwe, WC, Kim, SC, Lowe, MC, Breeden, C, Roberts, ME, Farris, AB, Strobert, EA, Jenkins, JB, Larsen, CP, Ford, ML, Townsend, R, Adams, AB
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2017
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5573634/
https://ncbi.nlm.nih.gov/pubmed/28502128
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ajt.14349
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller